Dr. Peter Senior, MD
Claim this profileUniversity of Alberta Clinical Islet Transplant Program
Studies Type 1 Diabetes
Studies Diabetes
3 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Peter Senior, MD is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
MTX228
for Type 1 Diabetes
MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study. The purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.
Recruiting1 award Phase 22 criteria
More about Peter Senior, MD
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Peter Senior, MD has experience with
- Implantation Of Nylon Catheter (Device-less Sentinel Unit)
- Sotagliflozin
- MTX228
Breakdown of trials Peter Senior, MD has run
Type 1 Diabetes
Heart Failure
Kidney Failure
Contrast-induced Nephropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Senior, MD specialize in?
Peter Senior, MD focuses on Type 1 Diabetes and Diabetes. In particular, much of their work with Type 1 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Peter Senior, MD currently recruiting for clinical trials?
Yes, Peter Senior, MD is currently recruiting for 2 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Peter Senior, MD has studied deeply?
Yes, Peter Senior, MD has studied treatments such as Implantation of Nylon catheter (Device-less sentinel unit), Sotagliflozin, MTX228.
What is the best way to schedule an appointment with Peter Senior, MD?
Apply for one of the trials that Peter Senior, MD is conducting.
What is the office address of Peter Senior, MD?
The office of Peter Senior, MD is located at: University of Alberta Clinical Islet Transplant Program, Edmonton, Alberta T6G 2E1 Canada. This is the address for their practice at the University of Alberta Clinical Islet Transplant Program.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.